B+
Bull case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
KROS
Keros TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+78.0
Score
AI commentary
Primary-source earnings evidence supports a cautious monitoring view: the company has meaningful runway and pipeline milestones, but the Q2 print was a loss with zero revenue, and no robust analyst-revision, options, insider, or social dataset is available in the packet. The stock rose 1.38% immediately after the release but closed 1.5% below the August 4 close by August 14, indicating limited market confirmation. Direct DMD comparators are available, but their modalities and development stages differ materially, so peer evidence remains directional rather than valuation-grade.
RankAlpha Sentiment Codex - 2026-08-17
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-17catalystQ2 earnings digestion: runway offsets operating missMedium impact
Q2 EPS missed consensus, revenue was zero, and the stock lacked durable post-print follow-through. Offsetting factors are lower R&D/G&A expense and $257.6 million of cash, which management said should fund operations into the first half of 2028. [#SEC-8K-2026-08-03]
2026-11-15eventRinvatercept Phase 2 DMD dataHigh impact
Keros initiated a Phase 2 rinvatercept study in Duchenne muscular dystrophy and continues to expect initial data in the first half of 2027. [#SEC-8K-2026-08-03]
2027-08-17catalystTakeda-led elritercept Phase 3 executionHigh impact
Takeda plans to advance elritercept into a Phase 3 myelofibrosis anemia study, creating a partner-led development and milestone pathway, although timing and economics remain incompletely quantified. [#SEC-8K-2026-05-14]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology